{
  "ticker": "IMU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969814",
  "id": "02969814",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250716",
  "time": "1245",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250716/pdf/06lvfhpkj7sk5t.pdf",
  "summary": "**Summary of ASX Announcement: Azer-cel Webinar**  \n- **Webinar Announcement**: Imugene to present latest Phase 1b trial data for azer-cel (CD19-targeted CAR T therapy).  \n- **Timing**: 11am AEST, 17 July 2025 (registration link provided).  \n- **No material data disclosed**: Announcement is procedural; clinical results not yet shared.  \n\nNo material trading or capital markets impact identified from this communication.",
  "usage": {
    "prompt_tokens": 949,
    "completion_tokens": 104,
    "total_tokens": 1053,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-16T04:10:33.331220"
}